Bioregulators & Organ Support
Pinealon
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Neural Bioregulator
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10, 20 mg
Dosing window: Morning
Receptor / target: CNS
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 10mg daily | Standard Khavinson protocol. Take in the morning. Repeat every 6 months. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1: Extended Protocol (Goal: general CNS oxidative defense restoration with minimized stimulation side effects; preferred for sensitive subjects)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 5mg daily in the morning | Smoother absorption profile. Lower daily peak: better tolerated by subjects sensitive to CNS activation effects. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: 30-Day Graduated Protocol (Goal: sensitive subjects, first cycle, or gentlest possible pan-CNS bioregulator introduction)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-5 | 1.0 mg 1x Daily, AM | |
| Days 6-14 | 1.5 mg 1x Daily, AM | |
| Days 15-20 | 2.0 mg 1x Daily, AM | |
| Days 20-25 | 2.5 mg 1x Daily, AM | |
| Days 25-30 | 3.0 mg 1x Daily, AM |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 3: Neuroprotection Pre-Loading Protocol (Goal: CNS oxidative defense pre-loading before planned surgical anesthesia, chemotherapy, or radiation therapy with known CNS toxicity)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 (3-4 weeks pre-procedure) | 10mg 1x Daily in the morning | Full standard course before the procedure to maximize CNS antioxidant enzyme expression and mitochondrial resilience. |
| Days 1-10 (4 weeks post-procedure) | 5mg 1x Daily in the morning | Recovery course at half-dose to support CNS recovery without overloading the recovering system. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 4: Sleep Architecture Restoration Protocol (Goal: circadian rhythm normalization and sleep quality improvement in subjects with age-related circadian dysregulation; run concurrent with DSIP at bedtime for additive effect)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-5 | 2mg 1x Daily in the morning | Morning administration mandatory: resets circadian phase of pineal-hypothalamic signaling. Sleep quality improvements typically begin by days 7-10. |
| Days 6-28 | 5mg 1x Daily in the morning | Extended cycle for maximum circadian restoration. Can run concurrent with DSIP at bedtime for additive sleep architecture normalization. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 5: Parkinson's Disease Neuroprotection Protocol (Goal: substantia nigra and basal ganglia oxidative defense support; requires neurologist supervision; concurrent with Cortagen for complete CNS coverage)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 1mg 1x Daily in the morning | Requires neurologist supervision. Conservative entry is mandatory. Monitor for any change in motor symptoms. |
| Weeks 3-4 | 2mg 1x Daily in the morning | |
| Weeks 5-12 | 5mg 1x Daily in the morning | Therapeutic dose targeting iron-catalyzed oxidative stress in substantia nigra. Run concurrent with Cortagen for complete CNS coverage. Assess UPDRS motor score at baseline, week 6, and week 12. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (CNS); route Subcutaneous; timing Morning. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active CNS infections (meningitis, viral encephalitis, brain abscess): exogenous CNS bioregulator activity modulating neuronal and microglial gene programs during active brain infection could alter the CNS immune response in unpredictable ways. Limited / unverified
- Uncontrolled seizure disorder: pan-CNS gene program modulation affecting neuronal excitability thresholds and mitochondrial energy generation in epileptic brain tissue has not been characterized; medical supervision required. Limited / unverified
- Active intracranial malignancy: Pinealon's pan-CNS neurotrophic and cell survival-supporting mechanisms have not been evaluated in brain tumor tissue that may express CNS cell surface receptors. Limited / unverified
- Concurrent use with narrow therapeutic index CNS drugs (phenytoin, carbamazepine, lithium, clozapine) where CNS state changes require stable pharmacological conditions: not a documented pharmacokinetic interaction but a clinical management consideration. Limited / unverified
- Known hypersensitivity to Pinealon (Glu-Asp-Arg tripeptide) or formulation excipients. Limited / unverified
- Pregnancy: CNS gene program modulation during fetal brain development has not been evaluated. Limited / unverified
- Active acute stroke (within 72 hours) without medical supervision: while animal data suggests Pinealon may be neuroprotective post-stroke, the timing, dosing, and interaction with thrombolytic or thrombectomy therapy in acute stroke management requires clinical supervision. Limited / unverified
Side effects (limited evidence)
- Mild headache on cycle initiation: the most commonly reported adverse effect; occurs in a minority of subjects in the first 1-3 days; related to the shift in CNS metabolic and oxidative activity as the bioregulator effect begins; typically resolves without intervention. Limited / unverified
- Increased dream vividness: pineal and circadian circuitry interaction produces more active REM architecture in some subjects; similar to Epithalon but typically milder. Limited / unverified
- Mild morning energy increase: the intended cortical activation effect of morning dosing; experienced as desired enhanced alertness by most subjects; can be overstimulating in a small minority. Limited / unverified
- Mild transient anxiety (rare): uncommon; a small subset of subjects reports mild anxious feelings in the first days of a new cycle; typically resolves after day 3-5 as CNS adaptation occurs. Limited / unverified
- Injection site mild reaction: standard subcutaneous peptide response; minimal. Limited / unverified
- No serious neurological adverse events documented in the Khavinson literature at standard protocol doses: the CNS safety profile across aging and neurological disease research populations is clean. Limited / unverified
- Unknown interaction profile with modern CNS pharmacology (novel antidepressants, antipsychotics, cognitive enhancers): Pinealon's research predates modern psychopharmacology; formal interaction data does not exist. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.